Gideon Capital Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Gideon Capital Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-1,713	Closed	-$256K	–	99
2019 Q4	$256K	Buy	+1,713	New	+$233K	0.09%	229
2019 Q1	–	Sell	-2,543	Closed	-$315K	–	444
2018 Q4	$315K	Buy	+2,543	New	+$377K	0.13%	251
2018 Q3	–	Sell	-3,347	Closed	-$577K	–	415
2018 Q2	$577K	Buy	+3,347	New	+$547K	0.29%	107
2017 Q4	–	Sell	-1,917	Closed	-$280K	–	345
2017 Q3	$280K	Buy	+1,917	New	+$290K	0.28%	162
2017 Q2	–	Sell	-1,592	Closed	-$231K	–	334
2017 Q1	$231K	Sell	1,592 -1,555	-49%	-$203K	0.14%	333
2016 Q4	$344K	Buy	+3,147	New	+$351K	0.22%	208
2014 Q3	–	Sell	-2,205	Closed	-$324K	–	317
2014 Q2	$324K	Buy	+2,205	New	+$306K	0.12%	193

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Gideon Capital Advisors's JAZZ Position: Q1 2020 in Review

Gideon Capital Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2020, closing a stake of 1,713 shares — an estimated $256K sold.

Gideon Capital Advisors first reported a position in JAZZ in Q2 2014 and held it in 7 quarters. The position peaked at $577K in Q2 2018. 408 funds tracked by Wall St. Rank hold JAZZ as of Q1 2020.

Gideon Capital Advisors reported no remaining Jazz Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Gideon Capital Advisors sold 1,713 Jazz Pharmaceuticals shares in Q1 2020, an estimated $256K.
Gideon Capital Advisors first reported a position in Jazz Pharmaceuticals in Q2 2014 and held it in 7 quarters.
Gideon Capital Advisors's Jazz Pharmaceuticals position peaked at $577K in Q2 2018.
408 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2020.

Based on Gideon Capital Advisors's 13F filing for Q1 2020.